Lung Microbiota Influence Responses to Anti-PD1 Therapy in a Preclinical Model of Non-small Cell Lung Cancer

被引：0
|
作者：
Chang, M. [1 ]
Mccormick, C. [1 ]
Kwok, B. [2 ]
Li, Y. [3 ]
Kyeremateng, Y. [1 ]
Aktas, A. [4 ]
Singh, R. [1 ]
Singh, S. [5 ]
Li, Q. [6 ]
Kugler, M. C. [7 ]
Pass, H. [8 ]
Sterman, D. H. [9 ]
Wu, B. G. [10 ]
Segal, L. N. [3 ]
Tsay, J. J. [11 ]
机构：
[1] NYU Langone Hlth, New York, NY USA
[2] NYU, New York, NY USA
[3] NYU, Sch Med, Med, New York, NY USA
[4] Vet Affairs New York Harbor Healthcare Syst, Med, New York, NY USA
[5] NYU, Sch Med, Pulm & Crit Care Med, New York, NY USA
[6] NYU, Sch Med, Div Pulm & Crit Care Med, New York, NY USA
[7] New York Univ Hosp Ctr, Med, New York, NY USA
[8] NYU Langone Hlth, Bronxville, NY USA
[9] NYU, Sch Med, NYU Langone Med Ctr, New York, NY USA
[10] Dept Internal Med, Div Pulm Crit Care & Sleep Med, New York, NY USA
[11] NYU, Sch Med, Pulm Crit Care, New York, NY USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A6691
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer
    Yamamoto, M.
    Kubo, S.
    Hirama, N.
    Teranishi, S.
    Tashiro, K.
    Seki, K.
    Maeda, C.
    Hiro, S.
    Kajita, Y.
    Sugimoto, C.
    Segawa, W.
    Nagayama, H.
    Nagaoka, S.
    Kudo, M.
    Kaneko, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1049 - S1050
  • [42] Novel anti-BMI-1 therapy in non-small cell lung cancer
    Krishnan, Indira
    Maroni, Giorgia
    Clohessy, Sean
    Savova, Virginia
    Bassal, Mahmoud
    Zilionis, Rapolas
    Csizmadia, Eva
    Kerwin, Clara M.
    Choi, Sun
    Meyerovitz, Claire V.
    Pandell, Nicole
    Fhu, Chee W.
    Zhang, Junyan
    Basseres, Daniela S.
    Magli, Cristina M.
    Goggi, Julian
    Welner, Robert S.
    Klein, Allon M.
    Weetall, Marla
    Branstrom, Art
    Bueno, Raphael
    Ali, Azhar
    Tenen, Daniel G.
    Levantini, Elena
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
    Yi, Chengxiang
    Bian, Dongliang
    Wang, Jue
    Hu, Shiqi
    Sun, Liangdong
    Yan, Yilv
    Wang, Suyu
    Shen, Ziyun
    Yu, Huansha
    Yang, Yong
    Zhou, Yirui
    Liu, Xiaogang
    Song, Nan
    Zhu, Yuming
    Zhao, Deping
    Jiang, Gening
    Duan, Liang
    He, Wenxin
    Xie, Dong
    Dai, Jie
    Zhang, Lele
    Zhang, Peng
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [44] Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
    Shen, Qian
    Qu, Jingjing
    Sheng, Lingyan
    Gao, Qiqi
    Zhou, Jianying
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Anti-PD1 or anti-PD-L1 antibodies alone or in combination with chemotherapy first-line treatment of advanced non-small cell lung cancer
    Zhang Xuexia
    Cai Xiaoping
    Zheng Hao
    THORACIC CANCER, 2022, 13 (07) : 1104 - 1105
  • [46] Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis
    Brito, Angelo Borsarelli Carvalho
    Camandaroba, Marcos Pedro Guedes
    de Lima, Vladmir Claudio Cordeiro
    THORACIC CANCER, 2021, 12 (07) : 1058 - 1066
  • [47] Changes of lung microbiota composition in patients with non-small cell lung cancer
    Ankudavicius, Vytautas
    Nikitina, Darja
    Lukosevicius, Rokas
    Skieceviciene, Jurgita
    Kupcinskas, Juozas
    Miliauskas, Skaidrius
    Zemaitis, Marius
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [48] Predictive immunological markers of anti-PD-1/PD-L1 therapy efficacy in non-small cell lung cancer
    Musaelyan, A. A.
    Lapin, S. V.
    Urtenova, M. A.
    Chistyakov, I. V.
    Nazarov, V. D.
    Akopov, A. L.
    Orlov, S. V.
    ANNALS OF ONCOLOGY, 2021, 32 : S1382 - S1382
  • [49] Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models
    Weinberg, U.
    Voloshin, T.
    Yitzaki, O. T.
    Kaynan, N.
    Giladi, M.
    Shteingauz, A.
    Munster, M.
    Cahal, S.
    Kirson, E. D.
    Palti, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] First line anti-PD1 checkpoint inhibitor in the management of patients with advanced non-small cell lung cancer: the Kent Cancer Network experience
    Angelis, V.
    Hunter, S.
    Shah, R.
    LUNG CANCER, 2019, 127 : S41 - S41
12345